Compare BTMD & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTMD | IXHL |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0M | 35.4M |
| IPO Year | 2021 | 2024 |
| Metric | BTMD | IXHL |
|---|---|---|
| Price | $1.15 | $2.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $2.61 | N/A |
| AVG Volume (30 Days) | ★ 100.4K | 49.6K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $192,219,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.16 |
| 52 Week High | $2.98 | $6.39 |
| Indicator | BTMD | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 34.19 |
| Support Level | $1.01 | $2.52 |
| Resistance Level | $1.68 | $3.89 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 69.53 | 21.82 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.